title: [The role of psychopharmacotherapy in combined treatment of patients with metabolic syndrome and depression].
abstract: OBJECTIVE
  To evaluate efficacy and tolerance of combined treatment with antidepressant cipramil in patients with metabolic syndrome (MS).
  
  
  METHODS
  We examined 23 MS patients with depression (mean age 47 +/- 7.4 years). For diagnosis and somatic state evaluation we used clinical, device and laboratory tests. The clinicopsychopathological method, MADRS and CGI scales were applied for assessment of mental state and treatment efficacy.
  
  
  RESULTS
  We achieved positive effects of 12-week combined somatotropic and psychotropic therapy on carbohydrate metabolism: a significant decrease of fasting blood glucose from 6.6 +/- 1.4 to 6.2 +/- 0.7 mmol and postprandial (2 hours after meal) glucose from 8.6 +/- 1.5 to 7.8 +/- 0.8 mmol/l, of waist circumference from 106.0 +/- 11.93 to 103.5 +/- 12.3 cm, body mass index from 32.5 +/- 4.54 to 31.4 +/- 4.76 kg m2, systolic blood pressure from 154.52 +/- 7.4 to 137.91 +/- 13.8 mm Hg and diastolic blood pressure from 90.1 +/- 6.2 to 81.0 +/- 6.6 mm Hg. A significant change in the levels of total cholesterol and triglycerides was not registered.
  
  
  CONCLUSIONS
  Administration of antidepressant in MS patients relieved depression. This improved carbohydrate metabolism, lowered blood pressure and body mass index.
authors.forename: E O
authors.initials: EO
authors.lastname: Poliakova
authors.forename: V E
authors.initials: VE
authors.lastname: Shimchik
authors.forename: V B
authors.initials: VB
authors.lastname: Mychka
authors.forename: I E
authors.initials: IE
authors.lastname: Chazova
mesh_terms: D000293:Adolescent; D018674:Adrenergic Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004232:Diuretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018674:Adrenergic Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000928:Antidepressive Agents; D001786:Blood Glucose; D004232:Diuretics